Compare Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF vs TG Therapeutics Inc — how do they compare? Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $19.7 (market cap $7.77B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF and TG Therapeutics Inc are close in size by market cap, and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is more actively traded (6,100,303 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF for 56 Days and TG Therapeutics Inc for 16 Days on average.
| PDBC | TGTX | |
|---|---|---|
Market Cap | $7.77B | $8.16B |
Volume | 6,100,303 | 1,735,121 |
52-Week High | $20.10 | $59.06 |
52-Week Low | $13.16 | $26.94 |
Typical Hold Time | 56 Days | 16 Days |
Sector | — | Health |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PDBC (Invesco Optimum Yield Diversified Commodity Strategy No K-1 ETF) trades at $19.66, up 1.29% with strong bullish technical signals from moving averages. The ETF has delivered impressive performance with 45.66% year-to-date gains through Q3 2026, driven by energy and agricultural commodity strength amid geopolitical tensions. Recent institutional activity shows mixed sentiment with significant short interest growth of 215.4% in September offset by multiple institutional purchases.
The commodity ETF outlook remains positive given ongoing geopolitical risks and defensive sector rotation, though elevated short interest and overbought RSI readings suggest near-term consolidation risk. Commodity super-squeeze warnings from HSBC highlight potential upside while defensive ETF inflows support continued institutional demand.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
